Du er her: IRF Publikationer Månedsbladet Rationel Farmakoterapi Årgange 2006 Referencer april

Print

Referencer til "Farmakoterapi ved urininkontinens og/eller blæretømningsbesvær"

Fra Rationel Farmakoterapi nr. 4 2006

  1. Abrams P, Cardozo L, Fall M et al. The standardisation of Terminology of Lower Urinary Tract Function.
    Neurourol Urodyn 2002:21:167-78.
  2. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life.
    Am J Manag Care 2000;6 (suppl.):580-90.
  3. Wern AJ, Rovner ES.  The overactive bladder: an overview for primary health care providers.
    In J Fertil Women’s Med 1999;44:56-66.
  4. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States.
    World J Urol 2003;20:327-36.
  5. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A polulation – based prevalence study.
    Br J Urol Int 2001;87:760-6.
  6. Chapple CR, Khullar V, Gabriel Z, Dooley JA. The effects of Antimuscarinic Treatment in overactive bladder: A Systematic Review and Meta-Analysis.
    European Urology 2005;48:5-26.
  7. Herbison P, Hay-Smith J, Ellis G, Moore K.
    BMJ 2003;326:841-4.
  8. Møller LA, Lose G, Antikolinergika til behandling af overaktiv blære. En omkostningstung behandling med tvivlsom klinisk effekt?
    Ugeskr. Læg 2003;47:165(47):4552-3.
  9. Parsons M, Cardoso L. Female Urinary Incontinence in Practice.
    Royal Society of Medicine Press Ltd 2004;pp.54-60.
  10. Meyhoff HH, Gerstenberg TC, Nordling J. Placebo – the Drug og Choice in Female Motor Urge Incontinence?
    Brit J Urol 1983;55:34-7.
  11. Appell RA, Abrams P, Drutz HP et al. Treatment of overactive bladder: longterm tolerability and efficacy of tolterodine.
    World J Urol 2001;19:141-7.
  12. Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutamin in patients with urge and mixed urinary incontinence.
    J Urol 2002;168:580-6.
  13. Chapple CR, Parkhouse H, Gardener C et al. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability.
    Br J Urol 1990;66:491-4.
  14. Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence.
    Urol Res 2001;29:118-25.
  15. Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis.
    J Neurol Neurosurg Psychiatry 1983;46:854-5.
  16. Lose G, Lalos O, Freeman RM, van Kerrebroeck P. Nocturia study group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind, placebo-controlled study in women.
    Am J Obstet Gynecol 2003;189:1106-13.
  17. Knudsen WB, Rittig S, Pedersen JB et al. Long-term treatment of nocturnal enuresis with desmopressin – influence on urinary output and haematological parameters.
    Neurourol Urodyn 1989;8:348-9.
  18. Robinson D, Cardozo L. Oestrogens and the lower urinary tract.
    BJOG 2004;111 (suppl 1):10-4.
  19. Walter S. Duloxetin. Et nyt præparat til patienter med urininkontinens.
    Ugeskr Læg 2005;48:4553-5.
  20. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali and the BPH-ALF group.  Alfuzosin for treatment af benign prostatic hypertrophy. Lancet 1991;337:1457-61.
  21. Chapple CR, Wyndaele JJ, Nordling J et al. On the behalf of the European Tamsulosin Study Group. Tamsulosin, the first prostate-selective alfa-1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155-67.
  22. Andersen JT, Ekman P, Wolf H et al. and the Scandinavian BPH Study Group. Can finasteride reverse the progress of benign prostatic hyperplesia? A two-year placebo-controlled study. Urology 1995;46:631-7.
  23. Roehrborn CG, Boyle P, Nickel JC et al on the behalf of the ARIA 3001, ARIA 3002 and ARIA 3003 study investigators. Efficacy and safety of a dual inhibitor of 5 alpha-reductase types 1 and 2 (dutasteride) in benign prostatic hyperplasia. Urology 2002;60:434-41.
  24. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003;349:2387-98.
  25. Athanasopoulos A, Gyftopoulos K, Giannitas K et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-6. 

Farmakoterapi ved urininkontinens og/eller blæretømningsbesvær


 

Siden sidst opdateret: 21. april 2006 Print Printspacer Tip en ven Tip en ven/kollega spacerTil top Til top